The Enterprise Value as of November 2024 (TTM) for Neurocrine Biosciences, Inc. (NBIX) is 12.62B

According to Neurocrine Biosciences, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 12.62B. This represents a change of -5.13% compared to the average of 13.31B of the last 4 quarters.

Neurocrine Biosciences, Inc. (NBIX) Historical Enterprise Value (quarterly & annually)

How has NBIX Enterprise Value performed in the past?

The mean historical Enterprise Value of Neurocrine Biosciences, Inc. over the last ten years is 7.50B. The current 12.62B Enterprise Value has changed 16.73% with respect to the historical average. Over the past ten years (40 quarters), NBIX's Enterprise Value was at its highest in in the June 2024 quarter at 14.27B. The Enterprise Value was at its lowest in in the December 2014 quarter at 1.67B.

Neurocrine Biosciences, Inc. (NBIX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Neurocrine Biosciences, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Neurocrine Biosciences, Inc. (NBIX) Average Enterprise Value

How has NBIX Enterprise Value performed in the past?

The current Enterprise Value of Neurocrine Biosciences, Inc. (NBIX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Neurocrine Biosciences, Inc. (NBIX) Enterprise Value vs. Peers

How is NBIX’s Enterprise Value compared to its peers?

Neurocrine Biosciences, Inc.’s Enterprise Value is greater than Amphastar Pharmaceuticals, Inc. (2.62B), greater than Collegium Pharmaceutical, Inc. (1.80B), greater than Ironwood Pharmaceuticals, Inc. (677.16M), greater than ANI Pharmaceuticals, Inc. (1.68B), greater than Deciphera Pharmaceuticals, Inc. (2.15B), greater than Alkermes plc (4.63B), greater than Avadel Pharmaceuticals plc (1.10B), greater than Intra-Cellular Therapies, Inc. (8.64B), greater than Dynavax Technologies Corporation (1.76B), greater than Pacira BioSciences, Inc. (1.21B), greater than Eagle Pharmaceuticals, Inc. (24.78M), greater than Prestige Consumer Healthcare Inc. (5.20B), greater than Evotec SE (1.30B), greater than Supernus Pharmaceuticals, Inc. (2.00B),

Build a custom stock screener for Neurocrine Biosciences, Inc. (NBIX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Neurocrine Biosciences, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Neurocrine Biosciences, Inc. (NBIX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Neurocrine Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.